PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $64.44 and traded as high as $65.04. PTC Therapeutics shares last traded at $64.91, with a volume of 724,936 shares.
Analysts Set New Price Targets
A number of equities research analysts have commented on PTCT shares. Weiss Ratings raised shares of PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Barclays raised their price objective on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Raymond James Financial set a $106.00 price objective on shares of PTC Therapeutics in a research report on Tuesday, October 20th. Zacks Research downgraded shares of PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada increased their target price on PTC Therapeutics from $75.00 to $77.00 and gave the company a “sector perform” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.23.
Read Our Latest Stock Report on PTCT
PTC Therapeutics Trading Up 0.2%
The firm’s 50-day moving average price is $64.12 and its two-hundred day moving average price is $70.27.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The company had revenue of $357.81 million for the quarter, compared to analysts’ expectations of $306.43 million. During the same quarter last year, the business earned $0.20 earnings per share. PTC Therapeutics’s revenue was up 69.6% on a year-over-year basis. As a group, research analysts expect that PTC Therapeutics, Inc. will post 0.49 earnings per share for the current fiscal year.
PTC Therapeutics declared that its Board of Directors has initiated a stock repurchase program on Tuesday, November 3rd that permits the company to buy back $500 million in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire up to 9.8% of its shares through open market purchases. Share buyback programs are generally an indication that the company’s board believes its shares are undervalued.
Insider Transactions at PTC Therapeutics
In related news, VP Mark Boulding sold 435 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total transaction of $27,909.60. Following the transaction, the vice president owned 105,272 shares in the company, valued at $6,754,251.52. This trade represents a 0.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $65.16, for a total value of $781,920.00. Following the transaction, the director directly owned 22,500 shares in the company, valued at approximately $1,466,100. This trade represents a 34.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 67,078 shares of company stock worth $4,616,538. Corporate insiders own 5.30% of the company’s stock.
Institutional Investors Weigh In On PTC Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PTCT. Allworth Financial LP purchased a new position in shares of PTC Therapeutics during the second quarter worth approximately $67,000. Harbor Investment Advisory LLC purchased a new stake in PTC Therapeutics in the 2nd quarter valued at $81,000. EverSource Wealth Advisors LLC raised its position in PTC Therapeutics by 16.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 151 shares during the last quarter. Quantbot Technologies LP acquired a new stake in PTC Therapeutics during the 2nd quarter worth $112,000. Finally, Jacobi Capital Management LLC acquired a new stake in PTC Therapeutics during the 3rd quarter worth $91,000.
PTC Therapeutics Company Profile
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
Recommended Stories
- Five stocks we like better than PTC Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
